
Teva will get US commercialisation rights for Eticovo upon close and infliximab in Q3 2027

The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine

The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

Plaque psoriasis affects over 125 million people worldwide

The agreement will expand the pipeline and builds on an existing partnership

The autoimmune disease affects approximately three to five million people globally

The companies aim to develop next-generation oral medicines for obesity and diabetes

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable